Determining the origin of lethal metastases in multifocal primary prostate cancer

Grant number: 1047581 | Funding period: 2013 - 2016



New biomarkers are required to accurately predict lethal prostate cancer from benign, indolent disaese that doesn't require expensive treatment. To do this relies on finding molecular differences between disease states. Advancements in high throughput genomic technologies enables us to now probe the lethal prostate cancer genome and transcriptome and distinguish this disease state from other forms of prostate cancer.

Related publications (12)